Profile data is unavailable for this security.
About the company
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies in the field of immune oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. DOS47 is a broad anti-cancer antibody drug conjugate (ADC) platform. DOS47 is based upon a naturally occurring enzyme isolated from the jack bean plant called urease that breaks down a natural substance found in the body, urea, into metabolites that include ammonium and hydroxyl ions. By doing so at the site of cancerous tissues in the body, DOS47 is designed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extracellular conditions that are believed to act to defend the tumor. Its pipeline includes L-DOS47 monotherapy NSCLC, L-DOS47 combo PEM/CARBO NSCLC, L-DOS47 DOXO combo Pancreas, and L-DOS47 combo Immune Checkpoints.
- Revenue in CAD (TTM)0.00
- Net income in CAD-6.14m
- Incorporated2008
- Employees9.00
- LocationHelix Biopharma Corp401 Bay Street,, Suite 2704,PO Box 4TORONTO M5H 2Y4CanadaCAN
- Phone+1 (905) 841-2300
- Fax+1 (905) 841-2244
- Websitehttps://www.helixbiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nurexone Biologic Inc | 0.00 | -5.62m | 37.67m | 8.00 | -- | 10.74 | -- | -- | -0.1081 | -0.1081 | 0.00 | 0.052 | 0.00 | -- | -- | -- | -183.97 | -213.78 | -235.34 | -596.97 | -- | -- | -- | -- | -- | -187.27 | 0.0096 | -- | -- | -- | 55.45 | -- | -- | -- |
| Avicanna Inc | 24.87m | -7.44m | 40.62m | 38.00 | -- | 1,130.84 | -- | 1.63 | -0.0804 | -0.0804 | 0.2714 | 0.0003 | 1.20 | 2.95 | 9.32 | 654,600.00 | -35.85 | -67.17 | -267.70 | -167.73 | 48.66 | 46.36 | -29.90 | -368.82 | 0.3316 | -8.88 | 0.1645 | -- | 314.82 | 169.57 | 40.67 | -- | -32.29 | -- |
| Microbix Biosystems Inc | 23.36m | 5.08m | 47.07m | 69.00 | 9.34 | 1.68 | 7.13 | 2.01 | 0.0369 | 0.0369 | 0.1695 | 0.205 | 0.6488 | 1.63 | 6.35 | -- | 14.10 | -0.9729 | 16.10 | -1.17 | 57.21 | 52.30 | 21.73 | -1.55 | 4.89 | 5.93 | 0.1849 | -- | -13.43 | 5.71 | -102.21 | -- | -3.56 | -- |
| KDA Group Inc | 204.14k | -876.18k | 48.26m | -- | -- | 3.35 | -- | 236.42 | -0.0027 | 0.0783 | 0.0013 | 0.0821 | 0.008 | -- | 0.0835 | -- | -4.63 | -17.96 | -8.47 | -44.69 | 33.32 | 26.76 | -574.97 | -28.00 | -- | -7.08 | 0.0606 | -- | -22.20 | -62.03 | 106.88 | -- | 31.67 | -- |
| MustGrow Biologics Corp | 4.71m | -423.96k | 52.14m | 0.00 | -- | 14.47 | -- | 11.07 | -0.0078 | -0.0078 | 0.0927 | 0.0726 | 0.9337 | -- | 32.60 | -- | -8.40 | -50.41 | -11.41 | -59.28 | -- | -- | -9.00 | -298.73 | 4.84 | -- | 0.1215 | -- | 72,619.13 | 372.54 | 87.84 | -- | -- | -- |
| Satellos Bioscience Inc | 0.00 | -23.05m | 55.30m | 12.00 | -- | 1.90 | -- | -- | -0.2044 | -0.2044 | 0.00 | 0.2585 | 0.00 | -- | -- | 0.00 | -53.45 | -107.22 | -57.45 | -136.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.33 | -- | 459.46 | -- |
| Helix Biopharma Corp. | 0.00 | -6.14m | 63.24m | 9.00 | -- | -- | -- | -- | -0.1478 | -0.1478 | 0.00 | -0.0079 | 0.00 | -- | -- | 0.00 | -449.73 | -261.49 | -2,225.00 | -- | -- | -- | -- | -- | -- | -265.96 | -- | -- | -- | -- | 4.16 | -- | -28.36 | -- |
| ZYUS Life Sciences Corp | 428.00k | -36.83m | 68.41m | 2.00 | -- | 4.20 | -- | 159.83 | -0.5247 | -0.5247 | 0.0061 | 0.2192 | 0.0074 | 0.075 | 0.5757 | -- | -63.34 | -57.88 | -88.37 | -71.19 | 46.50 | -16.16 | -8,604.67 | -10,367.37 | 0.1593 | -35.94 | 0.3955 | -- | 17.79 | 213.99 | -72.73 | -- | -- | -- |
| Covalon Technologies Ltd | 29.20m | -823.40k | 84.95m | -- | -- | 3.70 | 675.59 | 2.91 | -0.0335 | -0.0335 | 1.18 | 0.8786 | 1.10 | 1.77 | 5.15 | -- | -3.11 | -18.06 | -3.72 | -27.10 | 56.45 | 51.89 | -2.82 | -27.06 | 3.72 | -21.12 | 0.0474 | -- | 46.56 | -0.096 | 51.79 | -- | 12.21 | -- |
